Table 5.
Benzamides in clinical trials.
| Drug | Condition | Status | NCT number | Phases |
|---|---|---|---|---|
| Entinostat | Melanoma | Completed | NCT00185302 | Phase 2 |
| Entinostat | Cancer | Completed | NCT00020579 | Phase 1 |
| Entinostat | Leukemia, multiple myeloma and plasma cell neoplasm, MDS | Completed | NCT00015925 | Phase 1 |
| Entinostat + isotretinoin | Lymphoma, small intestine cancer | Completed | NCT00098891 | Phase 1 |
| Azacitidine + entinostat | Leukemia, myelodysplastic syndromes | Completed | NCT00101179 | Phase 1 |
| Azacitidine + entinostat | Colorectal cancer | Completed | NCT01105377 | Phase 2 |
| MGCD0103 + docetaxel | Solid cancer | Terminated | NCT00511576 | Phase 1 |
| Azacitidine + MGCD0103 | Acute myeloid leukemia (AML)|myelodysplastic syndrome (MDS) | Terminated | NCT00666497 | Phase 2 |
| MGCD0103 | Hodgkin's lymphoma | Terminated | NCT00358982 | Phase 2 |
| MGCD0103 | Myelodysplastic syndrome, acute myelogenous leukemia | Completed | NCT00324220 | Phase 1, 2 |
| MGCD0103 | Leukemia, myelodysplastic syndromes | Completed | NCT00324129 | Phase 1 |
| MGCD0103 | Tumors, non‐Hodgkin's lymphoma | Completed | NCT00323934 | Phase 1 |
| MGCD0103 | Lymphocytic leukemia, chronic | Completed | NCT00431873 | Phase 2 |
| MGCD0103 | Lymphoma | Completed | NCT00359086 | Phase 2 |
| MGCD0103 | Leukemia, myelodysplastic syndromes | Completed | NCT00324194 | Phase 1 |
| MGCD0103 | Myelogenous leukemia, acute, myelodysplastic syndromes | Terminated | NCT00374296 | Phase 2 |
| MGCD0103 + gemcitabine | Tumors | Completed | NCT00372437 | Phase 1, 2 |
| MGCD0103 + azacitidine | Hodgkin lymphoma | Terminated | NCT00543582 | Phase 2 |